Bone Cancer – Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Bone Cancer – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. Bone Cancer – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Bone Cancer.

– A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Bone Cancer.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bone Cancer Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Bone Cancer 7

Bone Cancer Therapeutics under Development by Companies 9

Bone Cancer Therapeutics under Investigation by Universities/Institutes 10

Mid Clinical Stage Products 11

Comparative Analysis 11

Early Clinical Stage Products 12

Comparative Analysis 12

Discovery and Pre-Clinical Stage Products 13

Comparative Analysis 13

Bone Cancer Therapeutics - Products under Development by Companies 14

Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes 15

Companies Involved in Bone Cancer Therapeutics Development 16

Debiopharm Group 16

Aileron Therapeutics, Inc. 17

Hawthorn Pharmaceuticals, Inc. 18

Virobay Inc. 19

KaloBios Pharmaceuticals, Inc. 20

Bone Cancer - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

Debio-0719 - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

VBY-825 - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

KB-003 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Angiotensin 1-7 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ATSP-7041 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MN-1 - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Astrogorgiadiol - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Bone Cancer Therapeutics - Drug Profile Updates 34

Bone Cancer Therapeutics - Dormant Products 36

Bone Cancer - Product Development Milestones 37

Featured News & Press Releases 37

Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37

Sep 12, 2012: Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec 37

Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37

Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 39

Jun 22, 2011: Celsion's ThermoDox Featured In Special Issue Of The Open Nanomedicine Journal 39

Jun 06, 2011: Merck And ARIAD Announce Presentation Of Results Of Phase III SUCCEED Trial At ASCO Annual Meeting 41

Jul 11, 2007: Amgen and Daiichi Sankyo Announce Agreement For Denosumab In Japan 42

Mar 14, 2002: Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN 43

Mar 14, 2002: Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 48

Disclaimer 48



List of Tables

Number of Products Under Development for Bone Cancer, H2 2013 7

Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8

Number of Products under Development by Companies, H2 2013 9

Number of Products under Investigation by Universities/Institutes, H2 2013 10

Comparative Analysis by Mid Clinical Stage Development, H2 2013 11

Comparative Analysis by Early Clinical Stage Development, H2 2013 12

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13

Products under Development by Companies, H2 2013 14

Products under Investigation by Universities/Institutes, H2 2013 15

Debiopharm Group, H2 2013 16

Aileron Therapeutics, Inc., H2 2013 17

Hawthorn Pharmaceuticals, Inc., H2 2013 18

Virobay Inc., H2 2013 19

KaloBios Pharmaceuticals, Inc., H2 2013 20

Assessment by Monotherapy Products, H2 2013 21

Assessment by Stage and Route of Administration, H2 2013 23

Assessment by Stage and Molecule Type, H2 2013 25

Bone Cancer Therapeutics - Drug Profile Updates 34

Bone Cancer Therapeutics - Dormant Products 36



List of Figures

Number of Products under Development for Bone Cancer, H2 2013 7

Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8

Products under Development by Companies, H2 2013 9

Products under Investigation by Universities/Institutes, H2 2013 10

Mid Clinical Stage Products, H2 2013 11

Early Clinical Stage Products, H2 2013 12

Discovery and Pre-Clinical Stage Products, H2 2013 13

Assessment by Monotherapy Products, H2 2013 21

Assessment by Route of Administration, H2 2013 22

Assessment by Stage and Route of Administration, H2 2013 23

Assessment by Molecule Type, H2 2013 24

Assessment by Stage and Molecule Type, H2 2013 25